Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its...
- Pre-enrollment activities underway for SER-109 ECOSPOR III clinical
study initiation; Company expects study start in mid-year -
- Continued pipeline progress with both SER-287 and SER-262 Phase 1b
studies; Data read-outs expected in the second half of 2017 -
- Conference call at 8 a.m. ET today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2017--
Therapeutics Inc. (NASDAQ:MCRB) today reported first quarter 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 1, 2017--
Seres Therapeutics Inc. (NASDAQ:MCRB) today announced that management
will participate in two upcoming investor conferences:
Bank of America Merrill Lynch Healthcare Conference on Tuesday, May
16, 2017 in Las Vegas, NV; presentation at 3 p.m. PDT.
UBS Global Healthcare Conference on Monday, May 22, 2017 in New York,
NY; presentation at 1:30 p.m. EDT.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 28, 2017--
Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will host a conference call and live audio webcast on Thursday, May 4,
2017 at 8:00 a.m. EDT to discuss first quarter 2017 results and provide
a general business update.
To access the conference call, please dial 844-277-9450 (domestic) or
336-525-7139 (international) and reference the conference ID number
11167224. To ...